Vertex Pharmaceuticals

28 PBAC submissions on file, active 2013–2025. 68% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Ivacaftor
  Rare disease · Recommended with restriction · 2025—
• Lumacaftor with ivacaftor
  Rare disease · Recommended with restriction · 2023—
• Elexacaftor/tezacaftor/ivacaftor
  Rare disease · Recommended with restriction · 2022—
• Lumacaftor and ivacaftor
  Rare disease · Noted · 2021—
• Tezacaftor with ivacaftor
  Rare disease · Recommended with restriction · 2019—
• Elexacaftor with tezacaftor and with ivacaftor, and ivacaftor
  Rare disease · Recommended with restriction · 2025—
• Lumacaftor/ivacaftor
  Rare disease · Not recommended · 2019—
• Vanzacaftor/tezacaftor/deutivacaftor
  Rare disease · Recommended with restriction · 2025—

Therapy area mix

Activity by year

2013 (2) · 2014 (2) · 2015 (2) · 2016 (3) · 2017 (1) · 2018 (2) · 2019 (5) · 2021 (4) · 2022 (1) · 2023 (2) · 2024 (1) · 2025 (3)

Rejection patterns

Across 5 Not recommended decisions on file.

• 1×Non-comparative open-label trial design with no head-to-head comparison to BSC
• 1×small sample size (n=60 Part B)
• 1×short duration (24 weeks) for a chronic disease
• 1×absence of comparator group prevented assessment of comparative efficacy/safety
• 1×uncertain comparative effectiveness versus deferring treatment to age 6 years